Vanessa Vogel-Farley, Executive Director of the Dup15q Alliance, discusses research in this rare disease, including the ARCADE trial, a phase 2 open-label pilot study. 

OV935 may be effective in controlling seizures. Four phase I studies successfully evaluated healthy participants’ abilities to tolerate OV935. ARCADE is the first Phase 2 study of OV935 in children and adults with CDD or Dup15q. As with any clinical research study, all potential risks and benefits cannot be known in advance.